Thirty-nine patients (15 outpatients and 24 inpatients) with a variety of skin diseases affecting variable areas of the body surface were treated with clobetasol propionate ointment (Dermovate). Before and after treatment the adrenal response to an intramuscular injection of tetracosactrin was tested and additional 9 am plasma cortisol levels were measured at intervals during treatment. A satisfactory initial therapeutic response was achieved in almost all cases during the trial period.
Introduction
It is well recognised that when corticosteroids are applied to the skin there may be sufficient percutaneous absorption to affect hypothalamic-pituitary-adrenal (HPA) function. This effect seems to parallel topical anti-inflammatory activity and is more likely to occur when large quantities of cream or ointment are applied to extensive areas of diseased skin.
Clobetasol propionate in a strength of 0 05%0 (Dermovate) is a highly effective corticosteroid preparation. ' 
Patients and methods
Twenty-three patients with psoriasis, 15 with dermatitis, and one with lichen planus were included. Children and patients who had received systemic steroid treatment during the previous six months were excluded. Ointment was applied to lesions up to twice daily without the use of occlusion (except in case 11). At the end of treatment the amount of ointment used was calculated.
HPA function in all patients was investigated using the short tetracosactrin test described by Wood et al,3 and 9 am plasma cortisol levels were assessed. Cortisol levels were considered abnormal if they were below 166 nmol/l (6 ,ug/100 ml). An abnormal response to an injection of 250 ,ug of tetracosactrin was recorded if after 30 minutes plasma cortisol levels had not risen by at least 193 nmol/l (7 ,ug/100 ml) to a level of 552 nmol/l (20 4g/100 ml) or more. Plasma cortisol estimations were carried out in the same laboratory using a fluorimetric method described by Spencer-Peet et al. 4 The extent of the disease was graded as follows: grade 1, small circumscribed lesions-for example, on elbows, knees, and scalp; grade 2, under 500% of body surface affected; grade 3, over 50% of body surface affected; grade 4, almost confluent lesions.
Results
The results are given in Adrenal function remained normal throughout the trial in only 14 patients (10 outpatients and 4 inpatients). Nineteen patients with initial normal 9 am plasma cortisol levels had abnormal levels for a variable period during treatment. In seven of these the plasma cortisol levels recovered, and in six of the seven the final tetracosactrin test was also normal. Of the 12 patients with depressed cortisol levels at the end of the trial half had an abnormal response to tetracosactrin.
Eight patients had a poor response to tetracosactrin at the beginning of the trial, and in four the 9 am plasma cortisol level was also abnormal. Evidence of improving adrenal function was present in three patients at the end of the trial (cases 17, 18, and 34). These eight patients had probably used large amounts of topical corticosteroids before starting the trial. of ointment used per week and plasma cortisol levels (table II) . Most inpatients were using large quantities of ointment: only six of the 24 inpatients were using less than 50 g a week and all had normal cortisol levels at the end of treatment, with five having a normal response to tetracosactrin. Four of the six had reduced 9 am plasma cortisol levels, however, at some earlier stage of treatment. The 11 inpatients whose plasma cortisol levels were low at the end of treatment were all using more than 50 g per week. Nine of the 15 outpatients, on the other hand, were using less than 50 g a week, and again all had normal plasma cortisol levels with normal responses to tetracosactrin at the end of the treatment. The three outpatients with low plasma cortisol levels at the end of treatment were all using more than 50 g a week.
Those patients with the most extensive skin disease tended to use the most ointment. patients 500 or less of the body surface area was diseased, and the patients used less than 50 g of ointment a week. It is also conceivable that the timing of their samples-at 14 and 28 days of treatment-allowed any early adrenal suppression to recover despite continuing treatment. This might also account for the apparent lack of systemic activity reported in the other studies cited.
When more than 50 g of clobetasol propionate ointment a week is being used clinicians should be aware of the possibility of adrenal suppression. In children these effects will probably occur with smaller quantities. While short-term adrenal suppression is probably of little clinical significance, long-term suppression should be prevented. Consequently, the most desirable method of using clobetasol propionate in many cases may be to give short intensive courses to induce rapid healing. The systemic and local side effects described by Staughton and August17 would then be avoided.
Introduction
The syndrome of oligomenorrhoea and hirsutism with polycystic changes in the ovaries has been recognised for many years,1 2 although in some cases no obvious ovarian changes are apparent.2 3 We report here, for the first time, three cases in which the only ovarian abnormality was a single, and possibly functional, cyst.
Patients and methods
The cases were selected from a study of patients likely to have the polycystic ovary syndrome. Hirsutism was estimated by a method on which 96% of a female outpatient population scored seven or below.4 No patient had clinical or biochemical evidence of thyroid, adrenal,
